AgomAb Therapeutics NV ADR Dossier - Source-backed chat

AgomAb Therapeutics NV ADR

AGMBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $11.10Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $546.7M

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Agomab Therapeutics is a clinical-stage biopharmaceutical company pioneering organ-restricted small molecule therapies to treat fibro-inflammatory diseases with high unmet medical needs. By engineering therapies that act locally in diseased tissues (such as the gastrointestinal tract or lungs) and rapidly degrade in systemic circulation, Agomab successfully bypasses the severe systemic toxicities that have historically limited the clinical utility of TGF-β/ALK5 pathway inhibitors. The company's lead asset, ontunisertib (AGMB-129), is a gut-restricted oral ALK5 inhibitor that demonstrated positive Phase 2a (STENOVA) results in fibrostenosing Crohn's disease (FSCD)—an indication with no approved pharmacological therapies where nearly half of patients eventually require surgery. Backed by a strong cash runway extending into 2029 following its $208 million Nasdaq IPO in February 2026, Agomab is well-positioned to advance its pipeline through critical clinical catalysts in the second half of 2026, including the initiation of a Phase 2b study for ontunisertib and a Phase 2 study for its inhaled lung-restricted ALK5 inhibitor, AGMB-447.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$28.00

Mean target$32.75

High · most bullish analyst$36.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$28.0020%

The STENOVA OLE study or the upcoming Phase 2b trial reveals unexpected long-term safety liabilities or systemic exposure of ontunisertib, eroding its key competitive advantage. Additionally, AGMB-447 fails to show sufficient target engagement or efficacy in the IPF cohort, or clinical trial initiations face significant regulatory and enrollment delays, accelerating cash burn and forcing dilutive financing before 2029.

Base CaseCentral scenario

$32.7550%

Matches the consensus mean

Agomab successfully initiates the Phase 2b NOV-ERA trial for ontunisertib in FSCD and the Phase 2 trial for AGMB-447 in IPF during the second half of 2026. The STENOVA open-label extension (OLE) 48-week data confirms sustained safety and tolerability, while the Phase 1b IPF cohort data for AGMB-447 supports its lung-restricted pharmacokinetic profile. The company maintains its projected cash runway into 2029, steadily advancing its pipeline in line with consensus expectations.

Bull CaseUpside scenario

$36.0030%

Ontunisertib's Phase 2b NOV-ERA trial achieves its primary endpoint of endoscopic passability at Week 24 with a highly favorable safety profile, establishing it as a breakthrough first-in-class disease-modifying therapy for FSCD. Simultaneously, AGMB-447's Phase 1b and subsequent Phase 2 trials in IPF demonstrate robust local target engagement and zero systemic safety signals, positioning Agomab as a multi-asset leader in fibrosis. Strong clinical execution attracts a lucrative global co-development partnership with a major pharmaceutical company, significantly boosting valuation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-mover advantage in fibrostenosing Crohn's disease (FSCD), a major complication affecting ~46% of Crohn's patients with no approved drug therapies.
Differentiated organ-restricted platform that minimizes systemic toxicities of ALK5/TGF-β inhibition through rapid plasma inactivation.
Robust balance sheet with approximately $208 million in gross proceeds from its February 2026 IPO, extending the cash runway into the first half of 2029.
Strong backing from premier healthcare and institutional investors, including Pfizer, EQT Life Sciences, Fidelity, and Sanofi.

Key Investment Risks

Clinical-stage risk: The company is unprofitable with no commercialized products, and its pipeline candidates require extensive further clinical testing.
Regulatory and trial design risk: The Phase 2b NOV-ERA trial utilizes a novel primary endpoint (endoscopic passability), which carries regulatory approval uncertainty.
Target-class risk: Historically, TGF-β pathway inhibitors have faced severe systemic safety hurdles; any sign of systemic toxicity would severely damage the investment thesis.

Thesis Invalidation Triggers

Failure of ontunisertib to meet its primary endpoint of endoscopic passability in the Phase 2b NOV-ERA trial.
Detection of clinically relevant systemic ALK5 inhibition or systemic toxicities in patients treated with ontunisertib or AGMB-447.
Significant delays in clinical trial initiation or patient enrollment for the Phase 2b FSCD or Phase 2 IPF studies.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.